Cargando…
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
BACKGROUND: Mutations in the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K), encoded by the PIK3CA gene, cause dysregulation of the PI3K pathway in 35–40% of patients with HR+/HER2– breast cancer. Preclinically, cancer cells harboring double or multiple PIK3CA mutations (mut) elicit...
Autores principales: | Hutchinson, Katherine E., Chen, Jessica W., Savage, Heidi M., Stout, Thomas J., Schimmoller, Frauke, Cortés, Javier, Dent, Susan, Harbeck, Nadia, Jacot, William, Krop, Ian, Trabucco, Sally E., Sivakumar, Smruthy, Sokol, Ethan S., Wilson, Timothy R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131374/ https://www.ncbi.nlm.nih.gov/pubmed/37101291 http://dx.doi.org/10.1186/s13073-023-01181-8 |
Ejemplares similares
-
ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
por: Chen, Jessica W., et al.
Publicado: (2023) -
Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations
por: Sivakumar, Smruthy, et al.
Publicado: (2023) -
Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
por: Rugo, Hope S., et al.
Publicado: (2023) -
Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations
por: Chen, Jessica W., et al.
Publicado: (2022) -
Mutations of PIK3CA in gastric adenocarcinoma
por: Li, Vivian Sze Wing, et al.
Publicado: (2005)